# P3BEP (NCT02582697)

> Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02582697
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: University of Sydney
- Conditions: Germ Cell Tumor
- Interventions: Bleomycin (active name: Bleomycin Sulfate); Etoposide; Cisplatin; Pegylated G-CSF (Pegfilgrastim); Filgrastim
- Enrollment: 500
- Primary outcome: Progression-free survival (disease progression or death)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=p3bep-nct02582697